Tirzepatide demonstrated superior cost-effectiveness compared to semaglutide for knee OA and obesity, with a $57,400 per QALY threshold. The Osteoarthritis Policy Model assessed cost-effectiveness, ...
CKD screening at age 55, combined with SGLT2 inhibitors, reduces kidney failure incidence and improves life expectancy across racial and ethnic groups. Non-Hispanic Black adults experience the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results